A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...